Literature DB >> 8662813

Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5.

A Parker1, J B Clarke, W H Busby, D R Clemmons.   

Abstract

Fibroblast extracellular matrix (ECM) contains two forms of insulin-like growth factor-binding proteins (IGFBPs), IGFBP-3 and IGFBP-5. These studies were undertaken to identify the regions within IGFBP-5 that mediate its binding to fibroblast ECM. Synthetic peptides were prepared that were homologous with two regions of basic amino acids within IGFBP-5 (Arg201-Arg218 and Ala131-Thr141). Increasing concentrations of both peptides competed with IGFBP-5 for binding to ECM but the Arg201-Arg218 peptide was more potent. Mutagenesis was used to define the effect of substituting for these basic residues on ECM binding. Substitution for two peptide B residues K134A and R136A reduced binding by 40%. Substitution of a single basic residue within the peptide A region (K211N) reduced binding to ECM by 49%. Substitution for K211N, K134A, and R136A reduced binding by 52%. More extensive substitutions in the peptide A region, e.g. K211N,R214A,K217A,R218N, resulted in a greater (e.g. 88%) decrease. The positional location of basic residues appeared to be more important than the total number of substitutions since the mutant K202N,K206A,R207A had a 79% reduction in ECM binding. Two basic regions of IGFBP-5 contribute to its binding to ECM, but the region containing amino acids 201-218 has a greater contribution. ECM binding is mediated by charged residues and acts to stabilize IGFBP-5 by protecting it from proteolysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662813     DOI: 10.1074/jbc.271.23.13523

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Damage control mechanisms in articular cartilage: the role of the insulin-like growth factor I axis.

Authors:  J A Martin; M B Scherb; L A Lembke; J A Buckwalter
Journal:  Iowa Orthop J       Date:  2000

2.  Quantitative characterization of binding of small molecules to extracellular matrix.

Authors:  Yufen Zhang; Viera Lukacova; Katie Reindl; Stefan Balaz
Journal:  J Biochem Biophys Methods       Date:  2006-02-17

3.  Development of a Dual-Functional Hydrogel Using RGD and Anti-VEGF Aptamer.

Authors:  Nan Zhao; Mark R Battig; Ming Xu; Xiuli Wang; Na Xiong; Yong Wang
Journal:  Macromol Biosci       Date:  2017-08-15       Impact factor: 4.979

Review 4.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 5.  Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland.

Authors:  M Delehedde; M Lyon; N Sergeant; H Rahmoune; D G Fernig
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

Review 6.  Insulin-like growth factor binding protein-5 in osteogenesis: facilitator or inhibitor?

Authors:  Aditi Mukherjee; Peter Rotwein
Journal:  Growth Horm IGF Res       Date:  2007-02-21       Impact factor: 2.372

7.  Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia.

Authors:  P Vorwerk; H Wex; B Hohmann; K Mohnike; U Schmidt; U Mittler
Journal:  Mol Pathol       Date:  2002-02

8.  Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I.

Authors:  A Parker; C Rees; J Clarke; W H Busby; D R Clemmons
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

9.  The heparin-binding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice.

Authors:  Gang Xi; Melissa A Solum; Christine Wai; Laura A Maile; Clifford J Rosen; David R Clemmons
Journal:  Endocrinology       Date:  2013-08-27       Impact factor: 4.736

10.  Mimicking pregnancy as a strategy for breast cancer prevention.

Authors:  Julia Santucci-Pereira; Christina George; David Armiss; Irma H Russo; Johana E Vanegas; Fathima Sheriff; Ricardo Lopez de Cicco; Yanrong Su; Patricia A Russo; Lucas T Bidinotto; Jose Russo
Journal:  Breast Cancer Manag       Date:  2013-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.